Ac Immune Sa

AC Immune SA is a clinical-stage biotech targeting neurodegenerative diseases. Its SupraAntigen and Morphomer platforms generate antibodies and vaccines with assets like Crenezumab (Phase II AD) and ACI‑24 (Phase II Down syndrome‑AD). Partners include Genentech, Biogen and Lilly

Headquarters: Switzerland (CHE)

Ac Immune Sa Logo
Company Profile
  • Employees: 133
  • HQ: Lausanne
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
ACIU Ac Immune Sa
Cap: 0.4B
EQUITY NGM USD CH0329023102 Active
📈
Home Login